CPRX Stock Price, Catalyst Pharmaceuticals Quote, Chart

Market Summary

USD15.11-0.23

Market Closed

-1.50%

CPRX Alerts

2 major insider sales recently.

CPRX Stock Price

View Fullscreen

CPRX RSI Chart

CPRX Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

24.94

Price/Sales (Trailing)

4.47

EV/EBITDA

17.2

Price/Free Cashflow

12.42

CPRX Price/Sales (Trailing)

CPRX Profitability

EBT Margin

23.73%

Return on Equity

18.41%

Return on Assets

15.19%

Free Cashflow Yield

8.05%

CPRX Fundamentals

CPRX Revenue

Revenue (TTM)

398.2M

Rev. Growth (Yr)

81.98%

Rev. Growth (Qtr)

7.67%

CPRX Earnings

Earnings (TTM)

71.4M

Earnings Growth (Yr)

36.8%

Earnings Growth (Qtr)

213.26%

Breaking Down CPRX Revenue

Last 7 days

-0.7%

Last 30 days

-10.6%

Last 90 days

3.8%

Trailing 12 Months

-8.4%

How does CPRX drawdown profile look like?

CPRX Financial Health

Current Ratio

2.88

CPRX Investor Care

Shares Dilution (1Y)

11.56%

Diluted EPS (TTM)

0.62

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	256.5M	302.9M	348.4M	398.2M
2022	153.7M	170.5M	191.8M	214.2M
2021	120.1M	126.9M	133.5M	140.8M
2020	119.0M	119.8M	118.2M	119.1M
2019	36.6M	54.6M	72.7M	102.3M
2018	0	0	0	18.5M
2010	0	0	0	489.0K

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Catalyst Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 08, 2024	tierney david s	sold	-392,000	15.68	-25,000	-
Apr 08, 2024	tierney david s	acquired	100,250	4.01	25,000	-
Mar 27, 2024	elsbernd brian	sold	-411,000	16.44	-25,000	chief compliance/legal officer
Feb 15, 2024	ingenito gary	acquired	-	-	10,000	chief med. & reg. officer
Feb 15, 2024	elsbernd brian	sold (taxes)	-	-	-2,353	chief compliance/legal officer
Feb 15, 2024	ingenito gary	sold (taxes)	-	-	-2,435	chief med. & reg. officer
Feb 15, 2024	del carmen jeffrey	sold (taxes)	-	-	-3,125	chief commercial officer
Feb 15, 2024	daly richard j	acquired	-	-	4,000	president and ceo
Feb 15, 2024	del carmen jeffrey	acquired	-	-	10,667	chief commercial officer
Feb 15, 2024	sundaram preethi	acquired	-	-	16,667	chief strategy officer

Which funds bought or sold CPRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Aspire Private Capital, LLC	unchanged	-	-17.00	319	-%
Apr 18, 2024	SJS Investment Consulting Inc.	reduced	-20.00	-21.00	64.00	-%
Apr 18, 2024	FARMERS & MERCHANTS INVESTMENTS INC	unchanged	-	-65.00	1,196	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	reduced	-7.57	-322,396	2,287,090	-%
Apr 17, 2024	Cyndeo Wealth Partners, LLC	added	18.44	206,997	1,888,000	0.16%
Apr 16, 2024	CAMPBELL NEWMAN ASSET MANAGEMENT INC	new	-	1,426,180	1,426,180	0.12%
Apr 16, 2024	TOTH FINANCIAL ADVISORY CORP	added	1,252	496,747	538,772	0.07%
Apr 16, 2024	VOISARD ASSET MANAGEMENT GROUP, INC.	unchanged	-	-844	15,462	0.01%
Apr 15, 2024	Brookstone Capital Management	unchanged	-	-29,150	534,086	0.01%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	reduced	-12.54	-3,661	17,789	-%

Are Funds Buying or Selling CPRX?

Are funds buying CPRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CPRX

No. of Funds

CPRX Alerts

2 major insider sales recently.

Unveiling Catalyst Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	6.68%	7,120,417	SC 13G/A
Feb 12, 2024	flynn james e	8.34%	8,888,901	SC 13G/A
Jan 25, 2024	state street corp	6.37%	6,787,332	SC 13G/A
Jan 22, 2024	blackrock inc.	14.8%	15,821,401	SC 13G/A
Feb 14, 2023	armistice capital, llc	0%	0	SC 13G/A
Feb 10, 2023	flynn james e	5.65%	5,884,448	SC 13G/A
Feb 09, 2023	vanguard group inc	6.50%	6,768,741	SC 13G
Feb 08, 2023	state street corp	7.57%	7,873,314	SC 13G/A
Jan 26, 2023	blackrock inc.	15.1%	15,690,326	SC 13G/A
Jan 20, 2023	blackrock inc.	15.1%	15,690,326	SC 13G/A

Recent SEC filings of Catalyst Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 10, 2024	4	Insider Trading
Apr 10, 2024	ARS	ARS
Apr 10, 2024	DEF 14A	DEF 14A
Apr 08, 2024	144	Notice of Insider Sale Intent
Mar 28, 2024	4	Insider Trading
Mar 27, 2024	144	Notice of Insider Sale Intent
Mar 13, 2024	8-K	Current Report
Feb 29, 2024	8-K	Current Report
Feb 28, 2024	10-K	Annual Report
Feb 21, 2024	8-K	Current Report

Peers (Alternatives to Catalyst Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.46	11.9	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.19	3.81	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.33	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Catalyst Pharmaceuticals Inc News

Latest updates

Catalyst Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	7.7%	111	103	100	85.00	61.00	57.00	53.00	43.00	38.00	36.00	36.00	30.00	31.00	29.00	30.00	29.00	30.00	31.00	29.00	12.00	1.00
Operating Expenses	-50.8%	69.00	140	53.00	50.00	30.00	32.00	25.00	26.00	26.00	22.00	21.00	20.00	-	-	-	-	-	-	18.00	13.00	15.00
S&GA Expenses	25.3%	42.00	34.00	28.00	30.00	14.00	14.00	13.00	16.00	13.00	12.00	12.00	13.00	13.00	10.00	11.00	10.00	11.00	8.00	9.00	8.00	7.00
R&D Expenses	-97.6%	2.00	84.00	4.00	4.00	4.00	8.00	4.00	3.00	5.00	4.00	4.00	3.00	4.00	4.00	4.00	4.00	6.00	5.00	5.00	3.00	8.00
EBITDA Margin	-	0.24*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	263.5%	12.00	-7.26	11.00	8.00	8.00	3.00	7.00	4.00	4.00	4.00	4.00	2.00	-2.71	-31.60	1.00	1.00	0.00	1.00	0.00	-	-
Earnings Before Taxes	222.8%	47.00	-38.02	49.00	37.00	33.00	26.00	28.00	17.00	13.00	14.00	16.00	10.00	9.00	12.00	10.00	11.00	8.00	14.00	11.00	-0.64	-14.50
EBT Margin	2.3%	0.24*	0.23*	0.48*	0.49*	0.49*	0.44*	0.43*	0.39*	0.37*	0.36*	0.36*	0.34*	-	-	-	-	-	-	-	-	-
Net Income	213.3%	35.00	-30.76	38.00	30.00	25.00	23.00	22.00	13.00	9.00	10.00	12.00	8.00	11.00	43.00	10.00	10.00	8.00	14.00	11.00	-0.64	-14.50
Net Income Margin	0.7%	0.18*	0.18*	0.38*	0.39*	0.39*	0.35*	0.32*	0.29*	0.28*	0.31*	0.59*	0.60*	-	-	-	-	-	-	-	-	-
Free Cashflow	23.3%	56.00	45.00	31.00	12.00	40.00	41.00	26.00	8.00	19.00	22.00	16.00	3.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	13.8%	470	413	444	407	376	333	267	247	238	223	209	197	192	175	131	118	112	97.00	78.00	61.00	60.00
Current Assets	14.2%	219	192	241	199	321	276	243	221	210	193	176	162	159	143	131	117	111	91.00	72.00	55.00	55.00
Cash Equivalents	13.8%	138	121	179	148	298	256	211	178	171	155	135	127	130	117	115	102	90.00	45.00	23.00	19.00	17.00
Inventory	73.1%	16.00	9.00	11.00	10.00	7.00	7.00	8.00	8.00	8.00	7.00	7.00	4.00	5.00	5.00	2.00	2.00	2.00	1.00	0.00	0.00	0.00
Net PPE	0.8%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	27.2%	82.00	65.00	69.00	74.00	75.00	63.00	26.00	27.00	31.00	25.00	20.00	19.00	23.00	18.00	20.00	18.00	25.00	19.00	15.00	10.00	10.00
Current Liabilities	31.6%	76.00	58.00	53.00	57.00	58.00	45.00	22.00	23.00	27.00	21.00	16.00	14.00	23.00	18.00	20.00	18.00	24.00	18.00	14.00	9.00	10.00
Shareholder's Equity	11.3%	388	349	375	334	300	270	241	220	207	199	189	179	170	157	111	100	88.00	78.00	63.00	51.00	51.00
Retained Earnings	40.3%	121	86.00	117	79.00	50.00	24.00	2.00	-15.62	-26.31	-32.54	-37.82	-46.33	-53.70	-65.14	-108	-118	-128	-136	-150	-161	-160
Additional Paid-In Capital	1.7%	266	262	258	254	250	246	239	236	233	231	227	225	223	222	220	218	216	214	213	212	211
Shares Outstanding	0.5%	107	107	107	106	105	103	103	103	103	103	104	104	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,341	-	-	-	666	-	-	-	551,582	-	-	-	445	-	-	-	368	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	23.3%	55,648	45,128	30,754	12,070	40,077	41,301	26,191	8,478	19,176	21,707	15,675	3,814	13,105	11,451	13,265	7,213	12,292	16,263	14,074	-8,016	-8,351
Share Based Compensation	11.5%	4,250	3,810	3,298	2,892	1,926	2,055	2,023	1,903	1,472	1,512	1,518	1,571	1,470	1,478	1,794	1,519	1,150	817	925	933	1,030
Cashflow From Investing	58.7%	-38,318	-92,817	-	-162,367	-	-132	-	-	-41.00	-68.00	-4,001	-6,911	-	-10,011	-	5,000	31,659	5,047	-9,930	10,449	14,143
Cashflow From Financing	93.4%	-665	-10,127	-214	149	2,253	3,984	-2,992	-1,551	-2,526	-2,098	-3,707	188	26.00	614	36.00	26.00	578	256	193	89.00	151
Buy Backs	-	-	-	-	-	-7.00	4.00	4,356	2,551	3,052	5,100	3,668	293	-	-	-	-	-	-	-	-	-

CPRX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Revenues:

Total revenues

$ 398,204

$ 214,203

$ 140,833

Operating costs and expenses:

Cost of sales

^[1]

51,967

34,393

21,884

Research and development

93,150

19,789

16,936

Selling, general and administrative

^[1]

133,710

57,085

49,628

Amortization of intangible assets

32,565

1,098

0

Total operating costs and expenses

311,392

112,365

88,448

Operating income

86,812

101,838

52,385

Other income, net

7,699

2,881

282

Net income before income taxes

94,511

104,719

52,667

Income tax provision

23,101

21,640

13,185

Net income

$ 71,410

$ 83,079

$ 39,482

Net income per share:

Basic

$ 0.67

$ 0.8

$ 0.38

Diluted

$ 0.63

$ 0.75

$ 0.37

Weighted average shares outstanding:

Basic

106,279,736

103,374,606

103,379,349

Diluted

113,753,154

111,375,631

107,795,585

Net income

$ 71,410

$ 83,079

$ 39,482

Other comprehensive income (Note 4):

Unrealized gain (loss) on available-for-sale securities, net of tax of $4, ($54) and $46, respectively

(10)

172

(179)

Comprehensive income

71,400

83,251

39,303

Product revenue, net [Member]

Revenues:

Total revenues

396,502

213,938

137,997

License and other revenue [Member]

Revenues:

Total revenues

$ 1,702

$ 265

$ 2,836

[1]	exclusive of amortization of intangible assets

CPRX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 137,636	$ 298,395
Accounts receivable, net	53,514	10,439
Inventory	15,644	6,805
Prepaid expenses and other current assets	12,535	5,167
Total current assets	219,329	320,806
Operating lease right-of-use asset	2,508	2,770
Property and equipment, net	1,195	847
License and acquired intangibles, net	194,049	32,471
Deferred tax assets, net	36,544	18,736
Investment in equity securities	16,489	0
Total assets	470,114	375,630
Current Liabilities:
Accounts payable	14,795	3,975
Accrued expenses and other liabilities	61,268	53,613
Total current liabilities	76,063	57,588
Operating lease liability, net of current portion	3,188	3,557
Other non-current liabilities	2,982	14,064
Total liabilities	82,233	75,209
Commitments and contingencies (Note 12)
Stockholders' Equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized: none issued and outstanding at December 31, 2023 and 2022	0	0
Common stock, $0.001 par value, 200,000,000 shares authorized; 107,121,549 shares and 105,263,031 shares issued and outstanding at December 31, 2023 and 2022, respectively	107	105
Additional paid-in capital	266,488	250,430
Retained earnings	121,272	49,862
Accumulated other comprehensive income (Note 4)	14	24
Total stockholders' equity	387,881	300,421
Total liabilities and stockholders' equity	$ 470,114	$ 375,630

About Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

CEO	Mr. Patrick J. McEnany
WEBSITE	catalystpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	82

Catalyst Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Catalyst Pharmaceuticals Inc? What does CPRX stand for in stocks?

CPRX is the stock ticker symbol of Catalyst Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Catalyst Pharmaceuticals Inc (CPRX)?

As of Fri Apr 19 2024, market cap of Catalyst Pharmaceuticals Inc is 1.78 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CPRX stock?

You can check CPRX's fair value in chart for subscribers.

What is the fair value of CPRX stock?

You can check CPRX's fair value in chart for subscribers. The fair value of Catalyst Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Catalyst Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CPRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Catalyst Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether CPRX is over valued or under valued. Whether Catalyst Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Catalyst Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CPRX.

What is Catalyst Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, CPRX's PE ratio (Price to Earnings) is 24.94 and Price to Sales (PS) ratio is 4.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CPRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Catalyst Pharmaceuticals Inc's stock?

In the past 10 years, Catalyst Pharmaceuticals Inc has provided 0.217 (multiply by 100 for percentage) rate of return.